Federal Judge Blocks RFK Jr.’s Childhood Vaccine Schedule Changes
A federal judge has temporarily halted a major effort by the Trump administration to overhaul the nation’s childhood vaccine schedule, marking a significant legal challenge to Health and Human Services Secretary Robert F. Kennedy Jr.’s push to reform federal immunization policy.
U.S. District Judge Brian Murphy, appointed during the Biden administration, issued a preliminary injunction blocking key components of the plan—including a sweeping restructuring of the Centers for Disease Control and Prevention’s vaccine advisory panel.
The ruling came after a lawsuit from the American Academy of Pediatrics and other medical groups, which argued that federal health officials acted outside their legal authority by scaling back the number of vaccines routinely recommended for children and reshaping the Advisory Committee on Immunization Practices (ACIP).
Murphy agreed, finding that the administration’s January changes failed to follow long-established legal and procedural requirements.
For decades, the judge noted, federal vaccine policy has relied on a structured, science-driven framework. Under Kennedy’s leadership, however, he wrote that the government “has disregarded those methods and thereby undermined the integrity of its actions.”
At the center of the dispute is a major shift announced earlier this year by the Department of Health and Human Services. The administration sought to streamline the childhood vaccine schedule down to 11 “consensus vaccines”—those commonly recommended across developed nations.
Under the revised approach, vaccines for measles, mumps, rubella, polio, diphtheria, tetanus, pertussis, Hib, pneumococcal disease, HPV, and varicella would remain standard. Others—including influenza, COVID-19, hepatitis A and B, rotavirus, and meningococcal vaccines—would no longer be universally recommended, instead left to individualized decisions between parents and physicians.
The policy shift followed a directive from President Donald J. Trump calling on federal agencies to reevaluate whether the U.S. vaccine schedule had expanded beyond international norms, particularly in the wake of declining public trust after the COVID-19 pandemic.
But Murphy’s ruling focused heavily on how the changes were implemented—not just the policy itself.
A key issue was Kennedy’s decision to remove all 17 prior members of ACIP and replace them with a new slate of 13 appointees. The judge found that the reconstituted panel failed to meet federal requirements for balance and expertise.
“A committee of non-experts cannot be said to embody ‘fairly balanced… points of view’ within the relevant scientific community,” Murphy wrote.
He further concluded that many of the new members lacked sufficient experience in vaccines, undermining the panel’s credibility and legal standing. As a result, he invalidated recent ACIP decisions, including moves to scale back recommendations for hepatitis B vaccines in newborns and to narrow COVID-19 guidance.
The ruling also forced the postponement of a scheduled ACIP meeting, delaying further action on the administration’s proposed reforms.
Supporters of the lawsuit praised the decision. Richard Hughes, an attorney representing the plaintiffs, called it “a great victory not only for vaccines and public health in the United States, but for science.”
Meanwhile, the administration signaled it will fight back. A spokesperson for HHS said officials expect the ruling to be overturned on appeal, arguing that the federal government retains broad authority to adjust public health recommendations—especially in response to shifting data and public concerns.
Allies of Kennedy’s “Make America Healthy Again” movement blasted the decision as an example of judicial overreach. Robert Malone, one of Kennedy’s appointees to the advisory panel, labeled Murphy a “rogue judge” and argued the administration has strong legal footing moving forward.
The case also carries major implications for the pharmaceutical industry. Vaccine manufacturers such as Pfizer, BioNTech, Moderna, Merck, Sanofi, and GSK have been closely monitoring the administration’s efforts, as changes to federal recommendations could significantly impact demand and insurance coverage.
Markets reacted modestly following the ruling, with some vaccine stocks ticking upward.
Notably, Murphy declined—for now—to block a separate order from Kennedy directing the CDC to stop recommending COVID-19 vaccines for healthy children and pregnant women, leaving that policy shift in place as legal battles continue.
The case is expected to move quickly through the appeals process, setting up a high-stakes showdown over the limits of executive authority, the role of federal courts, and the future direction of public health policy under President Trump’s second term.